Atrial Cardiopathy and Cryptogenic Stroke

Overview

Journal Front Neurol

Specialty Neurology

Date 2022 Mar 11

PMID 35273560

Authors

Yuji Kato

Shinichi Takahashi

Affiliations

Soon will be listed here.

Abstract

Recent advances in pathophysiology suggest that a pathological atrial substrate can cause embolic stroke even in patients without atrial fibrillation (AF). This pathological condition is called "atrial cardiopathy", which indicates atrial structural and functional disorders that can precede AF. The objective of this narrative review was to provide a current overview of atrial cardiopathy and cryptogenic stroke. We searched the PubMed database and summarized the recent findings of the identified studies, including the pathogenesis of atrial cardiopathy, biomarkers of atrial cardiopathy, relationship between atrial cardiopathy and cryptogenic stroke, and therapeutic interventions for atrial cardiopathy. Abnormal atrial substrate (atrial cardiopathy) that leads to AF can result in embolic stroke before developing AF, and may explain the source of cryptogenic stroke in some patients. Although there are several potential biomarkers indicative of atrial cardiopathy, P-wave terminal force in lead V1 (>5,000 μV ms), N-terminal pro-brain natriuretic peptide (>250 pg/ml), and left atrial enlargement are currently promising biomarkers for the diagnosis of atrial cardiopathy. Because the optimal combination and thresholds of biomarkers for diagnosing atrial cardiopathy remain uncertain, atrial cardiopathy represents a spectrum disorder. The concept of atrial cardiopathy appears to be most valuable as a starting point for therapeutic intervention to prevent stroke. Validation of the diagnosis of atrial cardiopathy and whether it can be used as a new therapeutic target for direct oral anticoagulants are currently being covered in the ARCADIA trial.

Citing Articles

Machine Learning Algorithm to Predict Atrial Fibrillation Using Serial 12-Lead ECGs Based on Left Atrial Remodeling.

Choi J, Song S, Kim H, Kim J, Park H, Jeon J J Am Heart Assoc. 2024; 13(19):e034154.

PMID: 39344663 PMC: 11681470. DOI: 10.1161/JAHA.123.034154.

Atrial cardiomyopathy revisited-evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American....

Goette A, Corradi D, Dobrev D, Aguinaga L, Cabrera J, Chugh S Europace. 2024; 26(9).

PMID: 39077825 PMC: 11431804. DOI: 10.1093/europace/euae204.

Cardioembolic Stroke: Past Advancements, Current Challenges, and Future Directions.

Kato Y, Tsutsui K, Nakano S, Hayashi T, Suda S Int J Mol Sci. 2024; 25(11).

PMID: 38891965 PMC: 11171744. DOI: 10.3390/ijms25115777.

Association between left atrial volume index and infarct volume in patients with ischemic stroke.

Homssi M, Balaji V, Zhang C, Shin J, Gupta A, Kamel H Front Neurol. 2023; 14:1265037.

PMID: 38053799 PMC: 10694187. DOI: 10.3389/fneur.2023.1265037.

Atrial Cardiomyopathy in Valvular Heart Disease: From Molecular Biology to Clinical Perspectives.

Molnar A, Santa A, Pasztor D, Merkely B Cells. 2023; 12(13).

PMID: 37443830 PMC: 10340254. DOI: 10.3390/cells12131796.

References

Kaab S, Darbar D, van Noord C, Dupuis J, Pfeufer A, Newton-Cheh C . Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J. 2009; 30(7):813-9. PMC: 2663727. DOI: 10.1093/eurheartj/ehn578. View

Healey J, Connolly S, Gold M, Israel C, Van Gelder I, Capucci A . Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012; 366(2):120-9. DOI: 10.1056/NEJMoa1105575. View

Tokunaga K, Hashimoto G, Mizoguchi T, Mori K, Shijo M, Jinnouchi J . Left Atrial Appendage Flow Velocity and Multiple Infarcts in Cryptogenic Stroke. Cerebrovasc Dis. 2021; 50(4):429-434. DOI: 10.1159/000514672. View

Healey J, Gladstone D, Swaminathan B, Eckstein J, Mundl H, Epstein A . Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA Neurol. 2019; 76(7):764-773. PMC: 6583060. DOI: 10.1001/jamaneurol.2019.0617. View

Kamel H, Bartz T, Elkind M, Okin P, Thacker E, Patton K . Atrial Cardiopathy and the Risk of Ischemic Stroke in the CHS (Cardiovascular Health Study). Stroke. 2018; 49(4):980-986. PMC: 5973804. DOI: 10.1161/STROKEAHA.117.020059. View

Jalini S, Rajalingam R, Nisenbaum R, Dave Javier A, Woo A, Pikula A . Atrial cardiopathy in patients with embolic strokes of unknown source and other stroke etiologies. Neurology. 2018; 92(4):e288-e294. DOI: 10.1212/WNL.0000000000006748. View

Llombart V, Antolin-Fontes A, Bustamante A, Giralt D, Rost N, Furie K . B-type natriuretic peptides help in cardioembolic stroke diagnosis: pooled data meta-analysis. Stroke. 2015; 46(5):1187-95. DOI: 10.1161/STROKEAHA.114.008311. View

Kamel H, Healey J . Cardioembolic Stroke. Circ Res. 2017; 120(3):514-526. PMC: 5312810. DOI: 10.1161/CIRCRESAHA.116.308407. View

Kamel H, Okin P, Elkind M, Iadecola C . Atrial Fibrillation and Mechanisms of Stroke: Time for a New Model. Stroke. 2016; 47(3):895-900. PMC: 4766055. DOI: 10.1161/STROKEAHA.115.012004. View

10.

Kamel H, Longstreth Jr W, Tirschwell D, Kronmal R, Broderick J, Palesch Y . The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke. 2018; 14(2):207-214. PMC: 6645380. DOI: 10.1177/1747493018799981. View

11.

Yaghi S, Chang A, Hung P, Mac Grory B, Collins S, Gupta A . Left Atrial Appendage Morphology and Embolic Stroke of Undetermined Source: A Cross-Sectional Multicenter Pilot Study. J Stroke Cerebrovasc Dis. 2018; 27(6):1497-1501. DOI: 10.1016/j.jstrokecerebrovasdis.2017.12.036. View

12.

Elkind M . Atrial Cardiopathy and Stroke Prevention. Curr Cardiol Rep. 2018; 20(11):103. DOI: 10.1007/s11886-018-1053-0. View

13.

Jin L, WEISSE A, Hernandez F, Jordan T . Significance of electrocardiographic isolated abnormal terminal P-wave force (left atrial abnormality). An echocardiographic and clinical correlation. Arch Intern Med. 1988; 148(7):1545-9. View

14.

Kamel H, Soliman E, Heckbert S, Kronmal R, Longstreth Jr W, Nazarian S . P-wave morphology and the risk of incident ischemic stroke in the Multi-Ethnic Study of Atherosclerosis. Stroke. 2014; 45(9):2786-8. PMC: 4146624. DOI: 10.1161/STROKEAHA.114.006364. View

15.

Kamel H, ONeal W, Okin P, Loehr L, Alonso A, Soliman E . Electrocardiographic left atrial abnormality and stroke subtype in the atherosclerosis risk in communities study. Ann Neurol. 2015; 78(5):670-8. PMC: 4624007. DOI: 10.1002/ana.24482. View

16.

Daccarett M, Badger T, Akoum N, Burgon N, Mahnkopf C, Vergara G . Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol. 2011; 57(7):831-8. PMC: 3124509. DOI: 10.1016/j.jacc.2010.09.049. View

17.

Tsang T, Abhayaratna W, Barnes M, Miyasaka Y, Gersh B, Bailey K . Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter?. J Am Coll Cardiol. 2006; 47(5):1018-23. DOI: 10.1016/j.jacc.2005.08.077. View

18.

Larsen B, Kumarathurai P, Falkenberg J, Nielsen O, Sajadieh A . Excessive Atrial Ectopy and Short Atrial Runs Increase the Risk of Stroke Beyond Incident Atrial Fibrillation. J Am Coll Cardiol. 2015; 66(3):232-241. DOI: 10.1016/j.jacc.2015.05.018. View

19.

Jalife J . Mechanisms of persistent atrial fibrillation. Curr Opin Cardiol. 2013; 29(1):20-7. DOI: 10.1097/HCO.0000000000000027. View

20.

Ntaios G, Swaminathan B, Berkowitz S, Gagliardi R, Lang W, Siegler J . Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. Stroke. 2019; 50(9):2477-2485. DOI: 10.1161/STROKEAHA.119.025168. View